Articles by Cody R. Barnett, MRA Director of Communications
The Hidden Costs of Cancer
The National Cancer Institute estimates that between 33 and 80% of cancer survivors exhaust their savings to finance their medical expenses. Up to three percent of survivors file for bankruptcy, 260 times more frequently than similar households not affected by cancer. Not only is this financially devastating for families, this hardship was the strongest predictor of the quality of life for cancer survivors.
The Microbiome, is it the Deciding Factor for Immunotherapy Success?
It's been nearly seven years since the first FDA-approved checkpoint inhibitor for melanoma came on the market and doctors, researchers, and patients all keep asking: "who is most likely to benefit from immunotherapy? How can we make this work for more people?" Thankfully, the answer may be closer than we thought and the trillions of bacteria, viruses, and other bugs - which make up our microbiome - may have something to say about it.
Creating a New Generation of Melanoma Models
We all can remember the eruption that happened when our 1st grade science teacher combined vinegar and baking soda together to represent a volcano. In some ways, this is just like experiments that take place every day in the search for better treatments, and ultimately a cure, for melanoma. In both instances, the researcher uses models to represent systems and phenomena that would otherwise be difficult or unethical to touch, see, or manipulate. Models are powerful things and we use them every day to make things easier to understand. In science, modeling is an essential component of our scientific process.
Introducing Clinical Trial Navigator: Start Searching Today
At MRA, we know that advancing science is our best bet in the fight against melanoma. More than 87,000 people in the US will be diagnosed with melanoma this year, and with these numbers on the rise, researchers are working harder than ever to find new and better treatment options. In fact, there are over 300 clinical trials happening in melanoma right now.
Connecting the Dots – Clinical Trials and Patient Engagement
MRA is thrilled to announce the launch of the Melanoma > Exchange, a melanoma treatment and research focused discussion group and support community. Through the Melanoma > Exchange, anyone touched by Melanoma can find support, ask questions, and build community among people who share a similar experience.
“Hands down, I’m alive today because of clinical trials”
Jamie Goldfarb didn’t think of herself as having cancer. Yes, she had been diagnosed with Stage II melanoma four years earlier and Stage III the following year, but the surgeries to remove it had been successful. The PET scans that followed had been normal. This wasn’t supposed to be happening. Jamie was now a tired new mom with an eleven-week old baby and she was ready to get back to work. But, her world would turn upside down when she learned that not only was melanoma back, but it had progressed to Stage IV and spread to her liver and pancreas.
Changing the Status Quo: Four Landmark Studies and their Implication for Melanoma Treatment
The crown jewel of the Melanoma Research Alliance has always been—and will always be—good science. Through science, we not only gain a better understanding of melanoma, but the ability to translate that understanding into better treatments, which in turn lead to a better quality of life for people with melanoma. At MRA, solid scientific leadership is at the forefront of everything we do. That’s why the MRA Board of Directors was thrilled to hear a presentation by fellow Board member and world-class researcher, Dr. Suzanne Topalian, on four landmark studies and their implications for melanoma treatment.
Ten Years of Powerful Research and Results
In 2007, when Debra Black was diagnosed with Stage II melanoma, there were few treatment options. In fact, for those diagnosed with late-stage melanoma, only two FDA-Approved treatment options existed, and they only provided a 16% chance at five-year survival. After dealing with her own health concerns, she and her husband knew that they could-and needed- to do more. That’s why later that year they worked with Mike Milken to found MRA and transform the melanoma landscape.
MRA Raises Millions of Dollars for Groundbreaking Melanoma Research
Normally, when people are at a Sotheby’s auction, they come to bid on beautiful and rare art. On Nov. 2nd, however, more than 240 people came together at Sotheby’s Headquarters in New York City to raise their paddle in the fight against melanoma. Together, participants raised over $20 million to further advance melanoma research.
“Seeing his Family Grow-Up Thanks to the Promise of Clinical Trials”
In August 2012, T.J. Sharpe walked into the emergency room with a fever. He’d been ill for a couple of days and didn’t want to get his four-week old son sick if he could avoid it. Sixteen days later, he left a full 30 pounds lighter and with a stage IV melanoma diagnosis.
About the Author
Cody R. Barnett, MRA Director of Communications
Cody R. Barnett joined the Melanoma Research Alliance (MRA) as Director of Communications in August of 2017. He works to develop and cultivate strategies, messages, and stories that propel MRA’s mission forward. Cody is responsible for media relations, web and social marketing, publications and materials development, and organizational branding. He is committed to using the power of visual, verbal, and written communications to promote MRA as a powerful force for advancing melanoma research.
Before joining the Melanoma Research Alliance, Cody served as Director of Communications at AIDS United, where he directed all internal, public, member, and online communications for the national HIV-focused organization. Previous to this, he managed digital communications for the Robert Wood Johnson Foundation’s Aligning Forces for Quality (AF4Q) initiative.
Cody earned his Master of Public Health (MPH), concentrating in health policy, from The George Washington University Milken Institute School of Public Health in 2013 and a Bachelor of Arts in political science from York College of Pennsylvania.